Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed CFO
Quarterly results
Director departure
Appointed director
Notes underwriting agrmnt
Acq. announced
CC transcript
|
|
INTERLEUKIN GENETICS INC (ILIU)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/14/2017 |
15-12B
| Form 15-12B - Securities registration termination [Section 12(b)]: |
| 08/04/2017 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 08/04/2017 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 08/04/2017 |
25
| Form 25 - Notification of the removal from listing and registration of matured, redeemed or retired securities: |
| 07/24/2017 |
8-K
| Quarterly results |
| 07/03/2017 |
8-K
| Form 8-K - Current report |
| 05/12/2017 |
4
| Toutain Stephan (Chief Commercial Officer) has filed a Form 4 on INTERLEUKIN GENETICS INC |
| 05/11/2017 |
10-Q
| Quarterly Report for the period ended March 31, 2017 |
| 05/01/2017 |
10-K/A
| Annual Report for the period ended December 31, 2016 [amend] |
| 04/18/2017 |
10-K/A
| Annual Report for the period ended December 31, 2016 [amend] |
| 04/17/2017 |
10-K
| Annual Report for the period ended December 31, 2016 |
| 04/03/2017 |
NT 10-K
| Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| 04/03/2017 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)] |
| 04/03/2017 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)] |
| 04/03/2017 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)] |
| 03/31/2017 |
8-K
| Form 8-K - Current report |
| 01/26/2017 |
4
| KORNMAN KENNETH S (President and CSO) has filed a Form 4 on INTERLEUKIN GENETICS INC |
| 01/26/2017 |
4
| Carbeau Mark B (CEO) has filed a Form 4 on INTERLEUKIN GENETICS INC |
| 01/26/2017 |
4
| WEAVER JAMES M (Director) has filed a Form 4 on INTERLEUKIN GENETICS INC |
| 01/26/2017 |
4
| Mills William C. III (Director) has filed a Form 4 on INTERLEUKIN GENETICS INC |
| 01/26/2017 |
4
| Toutain Stephan (Chief Commercial Officer) has filed a Form 4 on INTERLEUKIN GENETICS INC |
| 01/05/2017 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership [Amend] |
| 12/27/2016 |
CT ORDER
| Form CT ORDER - Confidential treatment order |
| 12/23/2016 |
8-K
| Form 8-K - Current report |
| 11/15/2016 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)] |
| 11/15/2016 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)] |
| 11/15/2016 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)] |
| 11/14/2016 |
10-Q
| Quarterly Report for the period ended September 30, 2016 |
| 11/07/2016 |
4/A
| Carbeau Mark B (CEO) has filed a Form 4 on INTERLEUKIN GENETICS INC |
| 10/24/2016 |
8-K
| Submission of Matters to a Vote of Security Holders |
| 10/21/2016 |
4
| Carbeau Mark B (CEO) has filed a Form 4 on INTERLEUKIN GENETICS INC |
| 10/21/2016 |
4
| Toutain Stephan (Chief Commercial Officer) has filed a Form 4 on INTERLEUKIN GENETICS INC |
| 10/11/2016 |
SC 13D/A
| Delta Dental Plan of Michigan, Inc. reports a 4.8% stake in Interleukin Genetics, Inc. |
| 09/30/2016 |
RW
| Form RW - Registration Withdrawal Request |
|
|
|